Lenangio 5mg capsules | Lenalidomide | Millionpharma
LENANGIO 5MG
 |
MYELODYSPLASTIC SYNDROME |
DESCRIPTION
Lenangio 5mg contains Lenalidomide as an active substance which belongs to thalidomide analogue.
Lenangio 5mg contains some pharmacological activities like immuno modulatory, anti-neoplastic, & anti-angiogenesis.
Lenangio 5mg is available in various strengths like 5mg, 10mg, 15mg & 25mg.
Lenangio 5mg is a prescription medicine; used under the supervision of medical oncologist.
Lenangio 5mg is used by combining with dexamethasone.
The most common indications of Lenangio 5mg capsules are;
Multiple myeloma: Lenangio 5mg capsules should be used in combination with dexamethasone.
Myelodysplastic syndrome: Lenangio 5mg capsules is used to treat this condition
Mantle cell lymphoma: Lenangio 5mg capsules is used for this condition, if patients are not responding to the Bortezomib treatment.
Lenangio 5mg includes in the restraint of tumor rot factor alpha arrangement, which support the T-cells and causes lessening serum levels of cytokines vascular endothelial development factor and fundamental fibroblast development factor.
Lenangio 5mg is additionally engaged with the preclusion of angiogenesis.
Lenalidomide is additionally empowered G1 cell cycle capture and apoptosis of ruinous cells.
Ingredients : Lenalidomide
Strength : 5mg
Manufactured : Dr. Reddy’s
Package : 10 capsules
DOSAGE MANAGEMENT
The usual prescribed dose of Lenangio in myelodysplastic syndromes is 10mg should be given as once a day.
For renal damaged patients;
In Patients with CrCl >60ml/min should not require dosage adjustment of Lenangio.
In Patients with CrCl 30 to 60ml/min, 5mg of Lenangio should be given orally as once a day.
In Patient with CrCl <30ml/min, 2.5mg of Lenangio should be administered orally as a once a day.
Dosage variation;
Thrombocytopenia:
Drops to <50000/mcL, therapy should be interrupted.
Back to > or equal to 50000/mcL, continue the Lenangio of 5mg/day.
Neutropenia;
Drops to <500/mcL, therapy should be postponed.
Back to > or equal to 500/mcL, treatment should be continuing to 5mg/day.
Multiple myeloma;
In this condition, Lenangio is concomitant with dexamethasone.
The usual dose of Lenangio is 25mg should be administered as once daily on day 1 to 21.
The dose of dexamethasone;
40mg of dexamethasone should be followed on day 1 to 4, 9 to 12 & 17 to 20 of each 28-day cycles.
Patient with >75 years, 20mg of dexamethasone should be recommended on day 1, 8, 15, & 22
Mantle cell lymphoma;
The advised dose of Lenangio for this condition is 25mg should be administered orally as once daily.
For renal damaged patients:
Patient with CrCl 30 to 60ml/min, 10mg of Lenangio should be administered as once daily.
Patient with CrCl <30ml/min, 15mg of Lenangio should be used for q48hr.
Pediatrics:
The potency & effectiveness of Lenalidomide has not been evaluated in pediatric patients with age of <18 years.
CONTACT US
MOBILE NO : +91-9940472902EMAIL : millionhealthpharmaceuticals@gmail.com
WEBSITE URL : https://millionpharma.com/lenangio-5mg.php
Comments
Post a Comment